

External Quality Assessment Scheme

Activated partial thromboplastin time, INR and fibrinogen Round 1, 2023

Specimens

Please find enclosed 2 lyophilized citrate plasma samples S001 and S002.

Caution

Quality control specimens derived from human blood must be handled with the same care as patient samples, i.e. as potential transmitters of serious diseases. The specimens are found to be HBsAg, HCVAb and HIVAgAb negative when tested with licensed reagents, but no known test method can offer complete assurance that the specimens will not transmit these or other infectious diseases.

Examinations

APTT
Fibrinogen
Prothrombin time (%)
Prothrombin time INR

Storage and use

After arrival store the unopened vials in a refrigerator (+2...8 °C). Open the vials carefully to prevent escape of dried material and reconstitute the contents in 1.0 mL of distilled water. Allow samples to stand for at least 15 minutes at room temperature before mixing. Mix the sample by inverting the tubes several times. Avoid foam formation. Samples are stable for 4 hours after reconstitution. Analyse as a patient sample.

Result reporting

Please enter the results and methods via LabScala (www.labscala.com). If you cannot find your instrument or reagent from the registry, please contact the EQA Coordinator.

S001



S002



2023-02-06

INSTRUCTIONS

Product no. 4330
LQ708123011-012/AT

If the kit is incomplete or contains damaged specimens, please report immediately to info@labquality.fi

The results should be reported no later than **February 23, 2023.**

Inquiries

EQA Coordinator
Iida Silvo
iida.silvo@labquality.fi

Labquality Oy




Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200
Fax + 358 9 8566 8280

info@labquality.fi
www.labquality.com



APTT | BLOKSEL 6100 (1)





	x_{pt}	sd	SEM	CV%	n
Bio-Ksel System APTTs	80.5 s	5.0	2.2	6.2	5
All methods	78.9 s	17.1	1.6	21.6	115

	x_{pt}	sd	SEM	CV%	n
Bio-Ksel System APTTs	33.5 s	0.5	0.2	1.6	5
All methods	29.7 s	4.2	0.4	14.3	115

Round	Sample	x_{pt}	Result	diff%	z-score
23/1	Specimen S002	33.5	33.4	-0.3%	-0.18
23/1	Specimen S001	80.5	79.6	-1.1%	-0.18

Fibrinogen |BIOKSEL 6100 (1)



Round	Sample	x_{pt}	Result	diff%	z-score
23/1	Specimen S002	3.72	3.52	-5.31%	-
23/1	Specimen S001	1.57	1.51	-3.97%	-


	x_{pt}	sd	SEM	CV%	n
Bio-Ksel System Fibrinogen	1.57 g/l	0.24	0.12	15.3	4
All methods	1.32 g/l	0.12	0.01	9.2	91

	x_{pt}	sd	SEM	CV%	n
Bio-Ksel System Fibrinogen	3.72 g/l	0.36	0.18	9.7	4
All methods	3.30 g/l	0.27	0.03	8.3	92

Thromboplastin time (%) | BLOKSEL 6100 (1)

SpecimenS001, Thromboplastin time (%)


The uncertainty of the assigned value is not negligible, and evaluations could be affected.



■ All method groups ■ Bio-Ksel PT Plus
● Own result: 36.00 (15.02.2023)
 Diff%: -3.36 | x_{pt} : 37.25
 Target area: 31.66-42.84 | Target: $\pm 15\%$


Specimen S002, Thromboplastin time (%)

The uncertainty of the assigned value is not negligible, and evaluations could be affected.



■ All method groups ■ Bio-Ksel PT Plus
● Own result: 97.00 (15.02.2023)
 Diff%: -0.77 | x_{pt} : 97.75
 Target area: 83.09-112.41 | Target: $\pm 15\%$

History



▲ diff%
▼ Due to the small number of results, the z score is not calculated

	x_{pt}	sd	SEM	CV%	n
Bio-Ksel PT Plus	37.25 %	2.06	1.03	5.5	4
All methods	24.40 %	4.80	0.51	19.7	90


	x_{pt}	sd	SEM	CV%	n
Bio-Ksel PT Plus	97.75 %	2.99	1.49	3.1	4
All methods	101.18 %	10.46	1.12	10.3	89

Round	Sample	x_{pt}	Result	diff%	z-score
23/1	Specimen S002	97.75	97.00	-0.77%	-
23/1	Specimen S001	37.25	36.00	-3.36%	-

Thromboplastin time INR | BLOKSEL 6100 (1)


SpecimenS001, Thromboplastin time INR

The uncertainty of the assigned value is not negligible, and evaluations could be affected.




■ All method groups ■ Bio-Ksel PT Plus
● Own result: 2.67 (15.02.2023)
 Diff%: 0.85 | x_{pt} : 2.65
 Target area: 2.25-3.04 | Target: $\pm 15\%$

Specimen S002, Thromboplastin time INR



■ All method groups ■ Bio-Ksel PT Plus
● Own result: 1.03 (15.02.2023)
 Diff%: 0.73 | x_{pt} : 1.02
 Target area: 0.87-1.18 | Target: $\pm 15\%$

History






▲ diff%
▼ Due to the small number of results, the z score is not calculated

	x_{pt}	sd	SEM	CV%	n
Bio-Ksel PT Plus	2.65 INR	0.09	0.04	3.3	4
All methods	2.57 INR	0.48	0.05	18.8	114

	x_{pt}	sd	SEM	CV%	n
Bio-Ksel PT Plus	1.02 INR	0.03	0.01	2.9	4
All methods	1.01 INR	0.05	<0.01	4.8	114

Round	Sample	x_{pt}	Result	diff%	z-score
23/1	Specimen S002	1.02	1.03	0.73%	-
23/1	Specimen S001	2.65	2.67	0.85%	-

APTT | BIOKSEL 6100 (2)






	x_{pt}	sd	SEM	CV%	n
Bio-Ksel System APTTs	80.5 s	5.0	2.2	6.2	5
All methods	78.9 s	17.1	1.6	21.6	115

	x_{pt}	sd	SEM	CV%	n
Bio-Ksel System APTTs	33.5 s	0.5	0.2	1.6	5
All methods	29.7 s	4.2	0.4	14.3	115

Round	Sample	x_{pt}	Result	diff%	z-score
23/1	Specimen S002	33.5	33.7	0.6%	0.37
23/1	Specimen S001	80.5	84.4	4.9%	0.79

Fibrinogen |BIOKSEL 6100 (2)



Round	Sample	x_{pt}	Result	diff%	z-score
23/1	Specimen S002	3.72	3.48	-6.39%	-
23/1	Specimen S001	1.57	1.58	0.48%	-


	x_{pt}	sd	SEM	CV%	n
Bio-Ksel System Fibrinogen	1.57 g/l	0.24	0.12	15.3	4
All methods	1.32 g/l	0.12	0.01	9.2	91

	x_{pt}	sd	SEM	CV%	n
Bio-Ksel System Fibrinogen	3.72 g/l	0.36	0.18	9.7	4
All methods	3.30 g/l	0.27	0.03	8.3	92

Thromboplastin time (%) | BLOKSEL 6100 (2)

SpecimenS001, Thromboplastin time (%)


The uncertainty of the assigned value is not negligible, and evaluations could be affected.



■ All method groups ■ Bio-Ksel PT Plus
● Own result: 35.00 (15.02.2023)
 Diff%: -6.04 | x_{pt} : 37.25
 Target area: 31.66-42.84 | Target: $\pm 15\%$


Specimen S002, Thromboplastin time (%)

The uncertainty of the assigned value is not negligible, and evaluations could be affected.



■ All method groups ■ Bio-Ksel PT Plus
● Own result: 94.00 (15.02.2023)
 Diff%: -3.84 | x_{pt} : 97.75
 Target area: 83.09-112.41 | Target: $\pm 15\%$

History



▲ diff%
▼ Due to the small number of results, the z score is not calculated

Round	Sample	x_{pt}	Result	diff%	z-score
23/1	Specimen S002	97.75	94.00	-3.84%	-
23/1	Specimen S001	37.25	35.00	-6.04%	-


	x_{pt}	sd	SEM	CV%	n
Bio-Ksel PT Plus	37.25 %	2.06	1.03	5.5	4
All methods	24.40 %	4.80	0.51	19.7	90

	x_{pt}	sd	SEM	CV%	n
Bio-Ksel PT Plus	97.75 %	2.99	1.49	3.1	4
All methods	101.18 %	10.46	1.12	10.3	89

Thromboplastin time INR | BLOKSEL 6100 (2)


SpecimenS001, Thromboplastin time INR

The uncertainty of the assigned value is not negligible, and evaluations could be affected.




■ All method groups ■ Bio-Ksel PT Plus
● Own result: 2.76 (15.02.2023)
 Diff%: 4.25 | x_{pt} : 2.65
 Target area: 2.25-3.04 | Target: ±15%

Specimen S002, Thromboplastin time INR



■ All method groups ■ Bio-Ksel PT Plus
● Own result: 1.06 (15.02.2023)
 Diff%: 3.67 | x_{pt} : 1.02
 Target area: 0.87-1.18 | Target: ±15%

History



▲ diff%
▼ Due to the small number of results, the z score is not calculated

	x_{pt}	sd	SEM	CV%	n
Bio-Ksel PT Plus	2.65 INR	0.09	0.04	3.3	4
All methods	2.57 INR	0.48	0.05	18.8	114

	x_{pt}	sd	SEM	CV%	n
Bio-Ksel PT Plus	1.02 INR	0.03	0.01	2.9	4
All methods	1.01 INR	0.05	<0.01	4.8	114

Round	Sample	x_{pt}	Result	diff%	z-score
23/1	Specimen S002	1.02	1.06	3.67%	-
23/1	Specimen S001	2.65	2.76	4.25%	-

Report info**Participants**

88 participants from 12 countries.

Report info

Your own result should be compared to others using the same method.

Assigned values (\bar{x}_p , target values) are means of the results where results deviating more than ± 3 standard deviation from the median are removed. The standard uncertainty (u) of

the assigned value is reported as standard error of the mean (SEM). Additionally, if the measurement uncertainty of the target value is large an automatic text is printed on the report: "The uncertainty of the assigned value is not negligible, and evaluations could be affected."

In case the client's result is the only one in the method group, no assigned value will be calculated, no target area shown, and no statistics calculated. In case there are only a few results in the client's own method group, the result can be compared to all method mean or to a group that is similar to the own method.





Results reported with $<$ or $>$ -signs cannot be included in the statistics.







For information on report interpretation and performance evaluation, please see the "EOAS Interpretation guidelines" LabScala User instructions (top right corner ?Help link).






Specimen S001 | APTT, s

Methodics	x_{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
Actin FSL	64.3	64.3	1.7	2.6	1.2	63.1	65.5	-	2
aPTT Screen	-	-	-	-	-	95.1	95.1	-	1
Bio-Ksel System APTTs	80.5	80.8	5.0	6.2	2.2	72.6	85.0	-	5
Dade Actin FS	68.7	68.3	0.9	1.4	0.4	67.7	70.4	-	7
Dade Actin FSL	66.5	65.9	6.6	9.9	1.4	52.1	81.1	-	22
HemosIL APTT-SP	78.6	79.6	5.3	6.7	1.3	66.1	87.2	-	17
HemosIL SynthASil	63.0	63.2	1.8	2.8	0.4	59.8	65.7	-	17
Hemostat aPTT-EL	-	-	-	-	-	57.8	57.8	-	1
MRX APTT	-	-	-	-	-	60.6	60.6	-	1
Pathromtin SL	109.3	108.9	5.8	5.3	1.3	100.4	123.9	1	22
SPA-PTT Automate	82.8	80.3	9.2	11.1	2.9	75.0	106.5	-	10
STA Cephascreen	76.7	75.7	6.2	8.1	3.1	71.4	84.0	-	4
STA-C.K. Prest	78.1	75.3	6.4	8.2	3.7	73.6	85.5	-	3
TriniClot aPTT HS	91.7	91.7	0.1	0.2	0.1	91.6	91.8	-	2
Yumizen G APTT Liq 4	-	-	-	-	-	72.1	72.1	-	1
All	78.9	75.3	17.1	21.6	1.6	52.1	123.9	-	115

Specimen S001 | APTT, s | histogram summaries in LabScala





















Specimen S001 | Fibrinogen, g/l

Methodics	x_{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
Bio-Ksel System Fibrinogen	1.57	1.55	0.24	15.3	0.12	1.31	1.89	-	4
Bio-Ksel System PT	-	-	-	-	-	1.40	1.40	-	1
Dade Actin FSL	1.09	1.09	0.08	7.2	0.06	1.03	1.14	-	2
Dade Actin SL	-	-	-	-	-	1.10	1.10	-	1
Dade Thrombin Reagent	1.25	1.26	0.07	5.9	0.01	1.09	1.39	-	34
Fibrinogen (Roche)	-	-	-	-	-	1.34	1.34	-	1
HemosIL Fibrinogen-C	1.43	1.41	0.08	5.4	0.04	1.37	1.54	-	4
HemosIL Q.F.A.	1.35	1.34	0.09	6.4	0.02	1.18	1.52	-	18
HemosIL RecombiPlasTin 2G	-	-	-	-	-	1.36	1.36	-	1
MRX APTT	-	-	-	-	-	1.42	1.42	-	1
Multifibren U	1.47	1.53	0.19	13.2	0.07	1.03	1.64	-	8
STA-Fib 2	1.28	1.28	0.01	1.1	0.01	1.27	1.29	-	2
STA-Liquid Fib.	1.33	1.32	0.05	3.4	0.01	1.27	1.43	-	13
Thromborel R, S	-	-	-	-	-	1.30	1.30	-	1
All	1.32	1.31	0.12	9.2	0.01	1.03	1.64	1	91

Specimen S001 | Fibrinogen, g/l histogram summaries in LabScala

















Specimen S001 | Thromboplastin time (%), %

Methodics	x_{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
Bio-Ksel PT Plus	37.25	37.50	2.06	5.5	1.03	35.00	39.00	-	4
Bio-Ksel System PT	-	-	-	-	-	37.00	37.00	-	1
Dade Innovin	24.67	24.20	0.90	3.6	0.52	24.10	25.70	-	3
HemosIL RecombiPlasTin 2G	28.64	27.50	5.23	18.2	1.85	22.90	34.70	-	8
Owrens PT/GHI	22.94	22.90	2.22	9.7	0.33	19.10	28.30	-	44
SPA 20	21.00	23.00	4.64	22.1	2.07	13.00	24.00	-	5
STA-NeoPTimal	48.70	48.70	<0.01	<0.1	<0.01	48.70	48.70	-	2
STA-SPA+	23.67	24.00	0.82	3.4	0.26	22.00	25.00	-	10
Thromborel R, S	25.32	21.70	8.24	32.5	2.38	18.00	44.50	-	12
Yumizen G PT Reco 10	-	-	-	-	-	23.50	23.50	-	1
All	24.40	23.70	4.80	19.7	0.51	13.00	39.00	3	90

Specimen S001 | Thromboplastin time (%), % | histogram summaries in LabScala


















Specimen S001 | Thromboplastin time INR, INR

Methodics	x_{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
aPTT Screen	-	-	-	-	-	2.86	2.86	-	1
Bio-Ksel PT Plus	2.65	2.64	0.09	3.3	0.04	2.56	2.76	-	4
Bio-Ksel System PT	-	-	-	-	-	2.58	2.58	-	1
Dade Innovin	2.59	2.60	0.02	0.8	<0.01	2.55	2.62	-	9
HemosIL RecombiPlasTin 2G	2.89	2.92	0.15	5.3	0.04	2.58	3.10	-	13
Hemostat Thromboplastin liquid	-	-	-	-	-	3.39	3.39	-	1
Owrens PT/GHI	2.20	2.20	0.14	6.3	0.02	1.84	2.47	-	45
SPA 20	2.41	2.26	0.47	19.4	0.21	2.13	3.24	-	5
STA-NeoPTimal	3.93	3.90	0.06	1.5	0.03	3.90	4.00	-	3
STA-SPA+	2.19	2.16	0.09	3.9	0.03	2.10	2.35	-	10
The Fiix Test	-	-	-	-	-	2.55	2.55	-	1
Thromborel R, S	3.24	3.26	0.34	10.4	0.08	2.50	3.83	-	20
Yumizen G PT Reco 10	-	-	-	-	-	2.49	2.49	-	1
All	2.57	2.42	0.48	18.8	0.05	1.84	3.90	1	114

Specimen S001 | Thromboplastin time INR, INR| histogram summaries in LabScala






















Specimen S002 | APTT, s

Methodics	x_{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
Actin FSL	24.3	24.3	<0.1	0.3	<0.1	24.2	24.3	-	2
aPTT Screen	-	-	-	-	-	32.5	32.5	-	1
Bio-Ksel System APTTs	33.5	33.7	0.5	1.6	0.2	32.6	34.0	-	5
Dade Actin FS	24.3	24.4	0.4	1.8	0.2	23.7	24.9	-	7
Dade Actin FSL	24.2	24.2	0.6	2.5	0.1	22.8	25.1	-	22
HemosIL APTT-SP	29.8	30.1	1.4	4.8	0.3	27.2	31.9	-	17
HemosIL SynthASil	30.1	29.7	1.2	4.2	0.3	28.2	32.5	-	17
Hemostat aPTT-EL	-	-	-	-	-	18.2	18.2	-	1
MRX APTT	-	-	-	-	-	31.7	31.7	-	1
Pathromtin SL	34.3	34.4	1.3	3.8	0.3	32.6	37.2	1	22
SPA-PTT Automate	34.4	33.9	2.3	6.6	0.7	32.0	40.4	-	10
STA Cephascreen	29.9	29.1	3.0	9.9	1.5	27.4	34.1	-	4
STA-C.K. Prest	31.9	31.8	0.5	1.6	0.3	31.4	32.4	-	3
TriniClot aPTT HS	32.1	32.1	0.3	0.9	0.2	31.9	32.3	-	2
Yumizen G APTT Liq 4	-	-	-	-	-	24.5	24.5	-	1
All	29.7	30.5	4.2	14.3	0.4	18.2	40.4	-	115

Specimen S002 | APTT, s | histogram summaries in LabScala






















Specimen S002 | Fibrinogen, g/l

Methodics	x_{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
Bio-Ksel System Fibrinogen	3.72	3.57	0.36	9.7	0.18	3.48	4.25	-	4
Bio-Ksel System PT	-	-	-	-	-	3.40	3.40	-	1
Dade Actin FS	-	-	-	-	-	2.60	2.60	-	1
Dade Actin FSL	2.86	2.86	0.52	18.3	0.37	2.49	3.23	-	2
Dade Actin SL	-	-	-	-	-	2.90	2.90	-	1
Dade Thrombin Reagent	3.26	3.27	0.18	5.7	0.03	2.90	3.59	-	34
Fibrinogen (Roche)	-	-	-	-	-	3.32	3.32	-	1
HemosIL Fibrinogen-C	3.54	3.47	0.23	6.4	0.11	3.34	3.86	-	4
HemosIL Q.F.A.	3.24	3.21	0.34	10.5	0.08	2.73	3.97	-	18
HemosIL RecombiPlasTin 2G	-	-	-	-	-	3.70	3.70	-	1
MRX APTT	-	-	-	-	-	3.20	3.20	-	1
Multifibren U	3.49	3.64	0.50	14.2	0.18	2.34	3.90	-	8
STA-Fib 2	3.17	3.17	0.10	3.1	0.07	3.10	3.24	-	2
STA-Liquid Fib.	3.30	3.30	0.12	3.6	0.03	3.10	3.47	-	13
Thromborel R, S	-	-	-	-	-	2.96	2.96	-	1
All	3.30	3.30	0.27	8.3	0.03	2.49	3.97	2	92

Specimen S002 | Fibrinogen, g/l histogram summaries in LabScala

















Specimen S002 | Thromboplastin time (%), %

Methodics	x_{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
Bio-Ksel PT Plus	97.75	98.00	2.99	3.1	1.49	94.00	101.00	-	4
Bio-Ksel System PT	-	-	-	-	-	97.00	97.00	-	1
Dade Innovin	101.70	101.80	1.05	1.0	0.61	100.60	102.70	-	3
HemosIL RecombiPlasTin 2G	95.72	96.97	4.28	4.5	1.51	86.00	99.10	-	8
Owrens PT/GHI	104.09	102.60	10.19	9.8	1.55	85.60	131.00	-	43
SPA 20	97.00	104.00	22.95	23.7	10.26	61.00	122.00	-	5
STA-NeoPTimal	14.05	14.05	0.21	1.5	0.15	13.90	14.20	-	2
STA-SPA+	108.18	110.00	6.19	5.7	1.96	97.00	114.00	-	10
Thromborel R, S	92.11	92.35	4.02	4.4	1.16	87.00	102.00	-	12
Yumizen G PT Reco 10	-	-	-	-	-	96.20	96.20	-	1
All	101.18	99.10	10.46	10.3	1.12	61.00	131.00	2	89

Specimen S002 | Thromboplastin time (%), %| histogram summaries in LabScala


















Specimen S002 | Thromboplastin time INR, INR

Methodics	x_{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
aPTT Screen	-	-	-	-	-	1.00	1.00	-	1
Bio-Ksel PT Plus	1.02	1.02	0.03	2.9	0.01	0.99	1.06	-	4
Bio-Ksel System PT	-	-	-	-	-	1.03	1.03	-	1
Dade Innovin	1.02	1.02	0.02	2.1	<0.01	0.99	1.05	-	9
HemosIL RecombiPlasTin 2G	1.03	1.03	0.04	3.7	0.01	0.97	1.10	-	13
Hemostat Thromboplastin liquid	-	-	-	-	-	1.07	1.07	-	1
Owrens PT/GHI	0.98	0.98	0.05	4.8	<0.01	0.87	1.07	-	45
SPA 20	1.03	0.99	0.12	11.5	0.05	0.94	1.24	-	5
STA-NeoPTimal	1.07	1.10	0.06	5.4	0.03	1.00	1.10	-	3
STA-SPA+	0.98	0.97	0.02	1.9	<0.01	0.96	1.01	-	10
The Fiix Test	-	-	-	-	-	1.03	1.03	-	1
Thromborel R, S	1.06	1.06	0.03	2.7	<0.01	0.99	1.10	-	20
Yumizen G PT Reco 10	-	-	-	-	-	1.02	1.02	-	1
All	1.01	1.01	0.05	4.8	<0.01	0.87	1.10	1	114

Specimen S002 | Thromboplastin time INR, INR| histogram summaries in LabScala







Report info**Participants**

88 participants from 12 countries.

Report info

Your own result should be compared to others using the same method.

Assigned values (\bar{x}_p , target values) are means of the results where results deviating more than ± 3 standard deviation from the median are removed. The standard uncertainty (u) of

the assigned value is reported as standard error of the mean (SEM). Additionally, if the measurement uncertainty of the target value is large an automatic text is printed on the report: "The uncertainty of the assigned value is not negligible, and evaluations could be affected."

In case the client's result is the only one in the method group, no assigned value will be calculated, no target area shown, and no statistics calculated. In case there are only a few results in the client's own method group, the result can be compared to all method mean or to a group that is similar to the own method.

Results reported with $<$ or $>$ -signs cannot be included in the statistics.

For information on report interpretation and performance evaluation, please see the "EOAS Interpretation guidelines" LabScala User instructions (top right corner ?Help link).

External Quality Assessment Scheme

APTT, fibrinogen and INR Round 1, 2023

Specimens

Sample S001 (LQ708123011) and sample S002 (LQ708123012) were lyophilized plasma samples.

Based on the previous tests and the results of this round, the samples are homogeneous, stable and suitable for the external quality assessment scheme.

The materials were sent without temperature control packaging.

Report info

Please see the description of the data analysis on the last page of the laboratory-specific histograms and Numerical Summary reports. It is important to read the Final report first, because it contains important information of the samples and results in each round.

Comments – EQA Coordinator

Four customers had clearly mixed the samples with each other, these results have been removed from the result processing.

APTT and Fibrinogen

Within the method groups, the result levels were mainly uniform in both samples, with the exception of a few deviating results.

Prothrombin time (%) and INR

As with previous rounds, users of STA-NeoPTimal reagent had markedly different PT (%) results compared to other methods. Participants are asked to note that the results are given in percentages, not seconds. The INR results were consistent.

End of report

2023-03-03

FINAL REPORT

Product no. 4330

Samples sent	2023-02-06
Round closed	2023-02-28
Final report	2023-03-03

Request for correction

Typing errors in laboratory's result forms are on laboratory's responsibility. Labquality accepts responsibility only for result processing. Requests must be notified by writing within three weeks from the date of this letter.

Authorized by

EQA Coordinator
Iida Silvo
iida.silvo@labquality.fi

Expert

Chief physician, Docent
Lotta Joutsu-Korhonen
HUSLAB, Helsinki, Finland

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200
Fax + 358 9 8566 8280

info@labquality.fi
www.labquality.com



Copyright © Labquality Oy

Labquality does not permit any reproduction for commercial purposes of any portion of the material subject to this copyright. Labquality prohibits any use of its name, or reference to Labquality EQA program, or material in this report in any advertising, brochures or other commercial publications. Labquality EQA data do not necessarily indicate the superiority of instruments, reagents, testing equipments or materials used by participating laboratories. Use of Labquality EQA data to suggest superiority or inferiority of equipments or materials may be deceptive and misleading. Proficiency test results are handled confidentially. Labquality will not issue any statements to third parties of the performance of laboratories in external quality assessment schemes unless otherwise agreed.